-  Using Asclet i s' proprietary U ltra- L ong- A cting P latform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinetic (PK) profile to ASC36 and ASC35 dosed alone  in head-to-head non-human primate studies. -  ASC36 monotherapy demonstrated approximately 32 % greater relative body weight reduction compared to eloralintide monotherapy in a head-to-head diet-induced obese (DIO) rat study, while ASC35 monotherapy demonstrated approximately 71% greater relative body weight reduction compared to tirzepatide monotherapy in a head-to-head DIO mouse study.

Ardmore Shipping Corporation ( ASC ) Q3 2025 Earnings Call November 5, 2025 10:00 AM EST Company Participants Gernot Ruppelt - CEO & Director Bart Kelleher - President & Director Conference Call Participants Jonathan Chappell - Evercore ISI Institutional Equities, Research Division Omar Nokta - Jefferies LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Ardmore Shipping's Third Quarter 2025 Earnings Conference Call. Today's call is being recorded, and an audio webcast and presentation are available in the Investor Relations section of the company's website, ardmoreshipping.com.

-Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts. -Phase Ib study data of ASC30 subcutaneous (SQ) injection showed that observed half-life reached 46 days for the treatment formulation (Injection A) and 75 days for the maintenance formulation (Injection B).

-In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3 -fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in humans. -ASC36 demonstrated approximately 91 % greater relative body weight reduction compared to petrelintide in a head-to-head diet-induced obese ( DIO ) rat study.

-Multiple posters being presented on Ascletis' small molecule and peptide obesity programs -Full analysis of 28-day multiple ascending dose study of oral GLP-1R small molecule agonist ASC30 as a late-breaking poster as well as ASC30 once-monthly treatment formulation and once-quarterly maintenance formulation HONG KONG , Oct. 27, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces multiple poster presentations of its obesity assets including ASC30, and combination of ASC31 and ASC47 at ObesityWeek® 2025 in Atlanta, Georgia. Presentation Details: Abstract Title: A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity Presentation Time:  November 4, 2025, 7:30 p.m.

- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG , Oct. 14, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently completed the pre-New Drug Application (NDA) consultation with China National Medical Products Administration (NMPA) for denifanstat (ASC40) for the treatment of moderate-to-severe acne vulgaris and plans to submit an NDA soon.

Ardmore Shipping (ASC) concluded the recent trading session at $11.7, signifying a -3.15% move from its prior day's close.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Ardmore Shipping (ASC) concluded the recent trading session at $12.07, signifying a -3.13% move from its prior day's close.

SAH, ASC, VIRT, SCSC and CIB have been added to the Zacks Rank #1 (Strong Buy) List on September 24, 2025.